The FDA Autobahn for New Drugs

The FDA is approving new drugs faster and with less evidence of their safety and effectiveness, according to a new JAMA study spanning the past 4 decades, NPR Shots reports.
2 or more pivotal clinical trials used to be the norm for approval; but almost half of the new drugs studied were based on just 1. Reliance on “surrogate measures”—like measuring tumor shrinkage instead of improvements in survival post-treatment—has also grown.
Approval turnaround has shrunk from 2.8 years in the late 1980s to 10.1 months in 2018.

Another concern: Drugmakers paid $908 million in review fees in 2018, making some experts worry about industry sway trumping patient benefits.
Are the fast-tracked drugs worthwhile? Some more than others, says Joshua Sharfstein, former FDA Principal Deputy Commissioner and a vice dean at the Johns Hopkins Bloomberg School of Public Health.
In an accompanying JAMA editorial, he lays out some ideas for reform.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top